HomeCompareSLRX vs EPRT

SLRX vs EPRT: Dividend Comparison 2026

SLRX yields 238.10% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRX wins by $339.54M in total portfolio value
10 years
SLRX
SLRX
● Live price
238.10%
Share price
$0.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$339.60M
Annual income
$185,958,933.65
Full SLRX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SLRX vs EPRT

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX
Annual income on $10K today (after 15% tax)
$20,238.10/yr
After 10yr DRIP, annual income (after tax)
$158,065,093.60/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, SLRX beats the other by $158,054,178.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + EPRT for your $10,000?

SLRX: 50%EPRT: 50%
100% EPRT50/50100% SLRX
Portfolio after 10yr
$169.83M
Annual income
$92,985,887.18/yr
Blended yield
54.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SLRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-14.5
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys
0
EPRT buys
0
No recent congressional trades found for SLRX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRXEPRT
Forward yield238.10%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$339.60M$63.4K
Annual income after 10y$185,958,933.65$12,840.73
Total dividends collected$322.91M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SLRX vs EPRT ($10,000, DRIP)

YearSLRX PortfolioSLRX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$34,510$23,809.52$11,205$505.18+$23.3KSLRX
2$113,715$76,790.22$12,672$682.46+$101.0KSLRX
3$358,160$236,484.38$14,490$930.48+$343.7KSLRX
4$1,079,339$696,107.48$16,786$1,282.69+$1.06MSLRX
5$3,115,421$1,960,529.07$19,753$1,791.56+$3.10MSLRX
6$8,622,197$5,288,696.04$23,677$2,541.64+$8.60MSLRX
7$22,905,117$13,679,366.22$29,008$3,672.99+$22.88MSLRX
8$58,470,750$33,962,275.23$36,463$5,425.08+$58.43MSLRX
9$143,588,724$81,025,021.41$47,238$8,221.57+$143.54MSLRX
10$339,598,869$185,958,933.65$63,385$12,840.73+$339.54MSLRX

SLRX vs EPRT: Complete Analysis 2026

SLRXStock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SLRX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHDSLRX vs JEPISLRX vs OSLRX vs KOSLRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.